BioEclipse Therapeutics™ today announced today the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously-delivered cancer therapy designed to target and destroy multiple cancer types and address disease recurrence....
BioEclipse Therapeutics CEO Dr. Pam Contag, shares with Dan Levine, host of The Bio Report, about the ability of cancers to return after treatment with immunotherapies, BioEclipse’s efforts to develop a multi-mechanistic immunotherapy to overcome that challenge, and why its approach may have broad application across a range of cancers....
Best practices and lessons learned during the drive to get a biopharmaceutical startup to the clinic as quickly as possible....
One of Life Science Leader’s newest editorial advisory board (EAB) members is Pamela Reilly Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics....
Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services....
BioEclipse Therapeutics™ today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Collaboratory, a 104,000 square-foot facility in Mountain View, CA. ...
In 2006, Contag cofounded ConcentRx (pronounced concen-tricks), but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. When asked about the details of what transpired between those 10 years, Contag was extremely transparent, sharing not only her frustrations but the wisdom she earned throughout this unusual business journey....
BioEclipse Therapeutics™ announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for the Company’s lead drug candidate, CRX100....